Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer

This study is testing an approach called adaptive stereotactic radiotherapy for men with low- or intermediate-risk prostate cancer. "Adaptive" means the radiation plan is adjusted during treatment to account for how the prostate moves or changes shape, which may reduce side effects and improve accuracy. **You may be eligible if...** - You are a male, 60 years or older - You have low or intermediate risk localized prostate cancer (confined to the prostate, stage T1–T2) - Your Gleason score is 6 or 7 and your PSA is less than 15 ng/mL - Radiotherapy has been recommended as your treatment - You are based in France and can communicate in French **You may NOT be eligible if...** - You cannot read, write, or understand French - You are already participating in another clinical trial that could affect results - You have had previous prostate surgery or bowel surgery that could affect outcomes - You are unable to give independent informed consent Talk to your doctor to see if this trial is right for you.